佐藤麻希、阿部憲介、山本善彦、諏江裕、伊藤俊広.
東日本大震災の経験から考える災害時の抗 HIV 薬供給と服薬支援策の課題.
日本エイズ学会誌. 16: 105-109, 2014.

阿部憲介、佐藤麻希、神尾咲留未、小山田光孝、塚本琢也、佐々木晃子、伊藤ひとみ、佐藤功、伊藤俊広.
当院における TDF 関連高 CK 血症の検討.
仙台医療センター医学雑誌. 4: 20-24, 2014.

木村哲、山本政弘、橋野聡、伊藤俊広、上平朝子.
HIV 感染症の検査・診断・治療における『連携』の諸問題を考える（座談会）.
医薬の門. 53:356-365, 2014.

豊嶋崇徳.
「HIV 感染症診断・治療・看護マニュアル　改訂第 9 版」（平成 25 年 10 月刊行）.
編集：北海道大学病院 HIV 感染症対策委員会.

豊嶋崇徳.
「平成 25 年度北海道 HIV/AIDS 医療者研修会記録集」（平成 25 年 9 月刊行）.
編集：北海道大学病院 HIV 感染症対策委員会.

遠藤知之、藤本勝也、吉田美穂、竹村龍、杉田純一、重松明男、近藤健、橋野聡、田中淳司、佐藤典宏、豊嶋崇徳.
HIV 感染者における梅毒血清反応と抗カルジオリピン抗体に関する検討.
日本エイズ学会誌. 15: 113-118,2013.

藤本勝也、遠藤知之、吉田美穂、竹村龍、近藤健、橋野聡、須田剛生、中馬誠、後藤了一、センテノ田村恵子、渡部恵子、大野稔子、石田禎夫、大竹孝明、宮城島拓人、小林一、堤豊、三宅高義、北川浩彦、佐藤典宏、豊嶋崇徳.
北海道内の HIV 感染症患者における HBV・HCV 重複感染の現状－拠点病院・診療施設アンケート調査結果－.
日本エイズ学会誌. 16: 18-27,201, 2014.

豊嶋崇徳.
「HIV・HCV 重複感染症診療ガイドライン　改訂第 6 版」（平成 26 年 12 月刊行）.
編集：北海道大学病院 HIV・HCV 重複感染症診療委員会.

豊嶋崇徳.
「HIV・HCV 重複感染患者さんの手引き　Heartec　改訂第 6 版」（平成 26 年 12 月刊行）.
編集：北海道大学病院 HIV・HCV 重複感染症診療委員会.

遠藤知之、藤本勝也、南昭子、吉田美穂、竹村龍、渡部恵子、坂本玲子、武内阿味、近藤健、橋野聡、清水力、豊嶋崇徳.
当院における HIV 感染者のビタミン D の検討.
日本エイズ学会誌. (in press).

永井孝宏、児玉泰光、黒川 亮、山田瑛子、村山正晃、池野 良、田邊嘉也、高木律男.
新潟大学医歯学総合病院歯科における HIV 感染症患者の臨床的検討.
日本エイズ学会誌. 16:148-154, 2014.

福山由美、市川誠一、大林由美子、杉浦亙、横幕能行.
愛知県におけるエイズ診療拠点病院初診患者の受診遅れと検査遅れに関連する要因.
日本エイズ学会誌. 15(2):119-127, 2013.

平野淳、高橋昌明、柴田雅章、野村敏治、横幕能行、杉浦亙.
結核を合併した日本人 HIV 感染症例に対するラルテグラビルカリウムとリファンピシン併用に関する検討.
日本エイズ学会誌. 15(1):36-39, 2013.

辻明宏、大郷剛、福井重文、米本仁史、上平朝子、中西宣文.
内服薬剤療法に抵抗性でエプロステノール静注療法が効果的であった HIV 関連肺動脈性肺高血圧症の 1 例.
Therapeutic Research. 34(9): 1176-1178, 2013.

木村哲、山本政弘、橋野聡、伊藤俊弘、上平朝子.
HIV 感染症の検査・診断・治療における「連携」の諸問題について考える。座談会.
医薬の門. 第 53 巻 第 6 号：357-365 2013 年 8 月.

上平朝子.
結核治療中に発症した急性 C 型肝炎.
HIV 感染症と AIDS の治療. VOL.4 No.2, P39-41, メディカルレビュー社, 2013 年 11 月.

白阪琢磨.
服薬をはじめるまえに第 5 版.
鳥居薬品㈱患者様用服薬支援冊子.（2014 年 5 月）.

白阪琢磨.
座談会「新しい治療ガイドライン－HIV 初感染・妊婦の治療、職業的 HIV 曝露時の感染予防も含めて－」.
HIV 感染症と AIDS の治療. 5(1)4-12（2014 年 5 月）.

矢嶋敬史郎、白阪琢磨.
連載 エイズに見られる感染症と悪性腫瘍（9）サルモネラ菌血症.
化学療法の領域. 30(7)（2014 年 7 月）.

白阪琢磨.
透析医療者のための HIV 感染症の知識～長期療養時代を見据えて～」.
鳥居薬品 第 59 回日本透析医学会学術集会・総会ランチョンセミナー15 記録冊子「医薬の門」.
54(5)2-6（2014 年 11 月）.

白阪琢磨.
特集 2「新規 HIV 感染者は過去 2 位。新規 AIDS 患者は過去最多。伸び率が高いのは、50 代以上です」.
健. 43(9)22-23.（2014 年 12 月）.

吉岡巖、金宮健翁、木下竜弥、鄭則秀、原田泰規、上平朝子、白阪琢磨、岡聖次.
抗 HIV 薬 Atazanavir 内服患者に発生した尿路結石症の検討.
泌尿器外科. 27(11):1823-1827（2014 年 11 月）.

白阪琢磨.
第 4 章 治療と管理・対応「抗 HIV-1 療法: いつ、どのように開始するか」.
最新医学別冊「新しい診断と治療の ABC65HIV 感染症と AIDS 改訂第 2 版」. 2014 年 12 月発行予定.

白阪琢磨.
抗 HIV 用薬.
治療薬ハンドブック 2015. 株式会社じほう（2015 年 2 月）.

須貝恵、鈴木智子、センテノ田村恵子、辻典子、井内亜紀子、濱本京子、吉用緑、山本政弘.
活用状況を考慮した「拠点病院診療案内」のあり方についての検討－拠点病院診療案内の活用に関するアンケート調査より－.
日本エイズ学会雑誌. 15 巻 3 号, 199-200, 2013.

須貝恵、辻典子、吉用緑、センテノ田村恵子、鈴木智子、井内亜紀子、濱本京子、山本政弘.
拠点病院の患者紹介現状から考える医療体制の課題－拠点病院から拠点病院以外の医療機関への患者紹介実績調査より－.
日本エイズ学会雑誌. 15 巻 3 号, 201-203, 2013.

塩野徳史（名古屋市立大学 看護学部国際保健看護学）、金子典代、市川誠一、山本政弘、健山正男、内海眞、木村哲、生島嗣、鬼塚哲郎.
MSM（Men who have sex with men）における HIV 抗体検査受検行動と受検意図の促進要因に関する研究.
日本公衆衛生雑誌. (0546-1766)60 巻 10 号, Page639-650(2013.10).

山本政弘.
精神科合併症－うつ（気分障害）、薬物依存－.
HIV 感染症と AIDS の治療. 5 巻 1 号, 57-59 2014.

辻麻理子、山本政弘、外川正生、井村弘子、和田裕一、塚原優己.
HIV 母子感染児の告知支援に関する解析と対策の評価.
日本エイズ学会誌. vol.16, No.3, 176-183, 2014（8）.

佐藤淳、宮腰昌明、北川善政.
HIV 感染症の口腔病変と歯科治療.
HIV 感染症　診断・治療・看護マニュアル　改訂第 9 版　北海道大学病院　HIV 感染症対策委員会. 2013 年 10 月.

吉田将律、吉川博政.
下顎骨骨折を契機にエイズ発症が判明した 1 例.
日本有病者歯科医療学会誌. 22(3) 2013 年 12 月.

佐藤淳.
歯科医院における院内感染対策の基礎知識.
月刊保団連. 通巻 1175 号, 10-15, 2014 年.

吉川博政、山本政弘、城崎真弓、長与由紀子、辻麻里子、前田憲昭.
九州医療センターにおける歯科医師,歯科衛生士 HIV/AIDS 研修プログラムについて.
日本エイズ学会誌. 16(2):110-114, 2014 年.

宮田泰.
愛知県歯科医師会における院内感染予防対策への取り組み.
日本歯科評論別冊「患者が求める医療安全、院内感染対策」. ヒョーロン・パブリッシャーズ. 160-167. 2014 年.

宇佐美雄司.
いま HIV/エイズはどうなっているか.
日本歯科評論. 平成 27 年 3 月号.(in press).

山中京子.
他者との協働：他職種連携の課題とその可能性.
児島亜紀子, 『主体と他者』. ミネルヴァ書房, 京都. 2015.（現在印刷中）.

高田知恵子.
秋田県における HIV カウンセリングの構築と展開－地方における地域心理臨床の実践－.
秋田大学教育文化学部研究紀要, 人文科学・社会科学部門. 69:pp53-61, 2014.

田中千枝子編著.
1 章現場研究と質的研究法.
社会福祉・介護福祉の質的研究法　実践者のための現場研究. 中央法規出版. pp002-007, 2013.

岩崎晋也、田中千枝子他.
医療ソーシャルワーク.
社会福祉のフロンティア. 有斐閣. pp189-194, 2014.

吉野宗宏、黒山政一、北原隆志、浜田幸宏、村木優一.
HIV 感染症.
感染症薬物療法トレーニングブック. じほう, 東京, 182-192, 2013 年.

吉野宗宏、白阪琢磨.
抗 HIV 薬モニタリング（TDM）.
化学療法の領域. 29(11): 99-107, 2013 年.

國本雄介、吉野宗宏、大石裕樹、原田幸子、井上正朝、佐藤麻希、内山真理子、齋藤直美、丸山一郎、下川千賀子、畝井浩子、松本俊治、増田純一、千田昌之、和泉啓司郎、宮本篤.
HIV 感染症診療における薬剤師介入が医療者側へもたらす効果に関する実態調査－エイズ治療ブロック拠点病院および ACC における検討－.
医療薬学. 40(8): 471-479, 2014 年.

研究成果の別刷

INTERNAL MEDICINE

□ ORIGINAL ARTICLE □

Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial

Takeshi Nishijima[1,2], Misao Takano[1], Michiyo Ishisaka[1], Hirokazu Komatsu[3], Hiroyuki Gatanaga[1,2], Yoshimi Kikuchi[1], Tomoyuki Endo[4], Masahide Horiba[5], Satoru Kaneda[6], Hideki Uchiumi[7], Tomohiko Koibuchi[8], Toshio Naito[9], Masaki Yoshida[10], Natsuo Tachikawa[11], Mikio Ueda[12], Yoshiyuki Yokomaku[13], Teruhisa Fujii[14], Satoshi Higasa[15], Kiyonori Takada[16], Masahiro Yamamoto[17], Shuzo Matsushita[2], Masao Tateyama[18], Yoshinari Tanabe[19], Hiroaki Mitsuya[20,21], Shinichi Oka[1,2], on behalf of the Epzicom-Truvada study team

Abstract

Objective To compare the efficacy and safety of fixed-dose abacavir/lamivudine (ABC/3TC) and tenofovir/emtricitabine (TDF/FTC) with ritonavir-boosted atazanavir (ATV/r) in treatment-naïve Japanese patients with HIV-1 infection.

Methods A 96-week multicenter, randomized, open-label, parallel group pilot study was conducted. The endpoints were times to virologic failure, safety event and regimen modification.

Results 109 patients were enrolled and randomly allocated (54 patients received ABC/3TC and 55 patients received TDF/FTC). All randomized subjects were analyzed. The time to virologic failure was not significantly different between the two arms by 96 weeks (HR, 2.09; 95% CI, 0.72-6.13; p=0.178). Both regimens showed favorable viral efficacy, as in the intention-to-treat population, 72.2% (ABC/3TC) and 78.2% (TDF/FTC) of the patients had an HIV-1 viral load <50 copies/mL at 96 weeks. The time to the first grade 3 or 4 adverse event and the time to the first regimen modification were not significantly different between the two arms (adverse event: HR 0.66; 95% CI, 0.25-1.75, p=0.407) (regimen modification: HR 1.03; 95% CI, 0.33-3.19, p=0.964). Both regimens were also well-tolerated, as only 11.1% (ABC/3TC) and 10.9% (TDF/FTC) of the patients discontinued the allocated regimen by 96 weeks. Clinically suspected abacavir-associated hypersensitivity reactions occurred in only one (1.9%) patient in the ABC/3TC arm.

Conclusion Although insufficiently powered to show non-inferiority of viral efficacy of ABC/3TC relative to TDF/FTC, this pilot trial suggested that ABC/3TC with ATV/r is a safe and efficacious initial regimen for HLA-B*5701-negative patients, such as the Japanese population.

[1]AIDS Clinical Center, National Center for Global Health and Medicine, Japan, [2]Center for AIDS Research, Kumamoto University Graduate School of Medical Sciences, Japan, [3]Department of Community Care, Saku Central Hospital, Japan, [4]Department of Hematology, Hokkaido University Hospital, Japan, [5]Division of Respiratory Medicine, Higashisaitama National Hospital, Japan, [6]Department of Gastroenterology, National Hospital Organization Chiba Medical Center, Japan, [7]Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Japan, [8]Department of Infectious Diseases and Applied Immunology, Research Hospital of the Institute of Medical Science, The University of Tokyo, Japan, [9]Department of General Medicine, Juntendo University School of Medicine, Japan, [10]Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan, [11]Department of Infectious Diseases, Yokohama Municipal Citizen's Hospital, Japan, [12]Immunology and Infectious Disease, Ishikawa Prefectural Central Hospital, Japan, [13]Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan, [14]Division of Blood Transfusion, Hiroshima University Hospital, Japan, [15]Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Japan, [16]Postgraduate Clinical Training Center, Ehime University Hospital, Japan, [17]Internal Medicine, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan, [18]Department of Infectious, Respiratory, and Digestive Medicine Control and Prevention of Infectious Diseases Faculty of Medicine, University of the Ryukyus, Japan, [19]Division of Infection Control and Prevention, Niigata University Medical and Dental Hospital, Japan, [20]Departments of Infectious Diseases and Hematology, Kumamoto University Graduate School of Medical Sciences, Japan and [21]Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, USA

Received for publication October 18, 2012; Accepted for publication December 17, 2012

Correspondence to Dr. Shinichi Oka, oka@acc.ncgm.go.jp

Intern Med 52: 735-744, 2013 DOI: 10.2169/internalmedicine.52.9155

Key words: HIV-1 infection, tenofovir/emtricitabine, abacavir/lamivudine, ritonavir-boosted atazanavir, treatment-naïve Asian patients, HLA-B*5701-negative

(Intern Med 52: 735-744, 2013)
(DOI: 10.2169/internalmedicine.52.9155)

Introduction

The fixed-dose combinations of tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg and abacavir sulfate 600 mg/lamivudine 300 mg are components of antiretroviral therapy for treatment-naïve patients with HIV-1 infection in developed countries (1, 2). The efficacy and safety of tenofovir/emtricitabine (TDF/FTC) and abacavir/lamivudine (ABC/3TC) remain the focus of ongoing debate. The ACTG 5202 trial demonstrated that the viral efficacy of ABC/3TC is inferior to that of TDF/FTC among treatment-naïve patients with a baseline HIV viral load of >100,000 copies/mL receiving efavirenz or ritonavir-boosted atazanavir as a key drug (3). On the other hand, the HEAT study showed that the viral efficacy of ABC/3TC is not inferior to that of TDF/FTC, regardless of the baseline viral load when used in combination with lopinavir/ritonavir (4).

With regard to safety, the occurrence of ABC-associated serious hypersensitivity reactions, the most important adverse effect of ABC affecting 5-8% of patients, has limited its use (5). However, screening for HLA-B*5701 or prescribing ABC in HLA-B*5701-negative populations, such as the Japanese, can reduce the incidence of immunologically-confirmed hypersensitivity to 0% (6, 7). Another negative aspect of ABC use is its association with myocardial infarction, as reported by the D:A:D study (8). However, the possible association of myocardial infarction with ABC was not confirmed by a recent meta-analysis report of the US Food and Drug Administration (9). On the other hand, renal proximal tubular damage leading to renal dysfunction and a loss of phosphate, which can result in decreased bone mineral density, is a well-known adverse effect of TDF (10-14).

Taking this background into account, the American Department of Health and Human Services (DHHS) Guidelines place TDF/FTC as the preferred drug and ABC/3TC as an alternative choice, whereas other international guidelines, including the European AIDS Clinical Society (EACS) Guidelines and the Japanese Guidelines, recommend both TDF/FTC and ABC/3TC as preferred choices (1, 2, 15).

Randomized control trials comparing TDF/FTC and ABC/3TC have been conducted in the US and Europe, but not in other parts of the world (4, 16, 17). The efficacy and safety of these two fixed-dose regimens in patients with different genetic backgrounds and body statures might not be similar to the results of previous trials, especially considering that the prevalence of HLA-B*5701 is zero in the Japanese population (7). Moreover, the degree of decrement in the renal function with TDF is larger in patients with a low body weight, such as the Japanese, which might limit the use of TDF in patients with a high risk for renal dysfunction (18-20).

Based on the above described background, the present randomized trial was originally designed in 2007 to elucidate whether the viral efficacy of ABC/3TC is not inferior to that of TDF/FTC with ritonavir-(100 mg) boosted atazanavir (300 mg) in treatment-naïve Japanese patients, whose body weight is much lower than Whites or Blacks (21). However, the independent data and safety monitoring board (DSMB) recommended that the protocol be modified to examine the efficacy, safety and tolerability among Japanese patients with HIV-1 infection for 96 weeks as a pilot trial because only 109 patients were enrolled and randomized at the end of the enrollment period despite a planned sample size of 240 patients, primarily due to the above mentioned negative reports of ABC use in the D:A:D study and ACTG 5202 (3, 8).

Materials and Methods

This clinical trial was designed and reported according to the recommendations of the Consolidated Standard of Reporting Trials (CONSORT) statement (22). The protocol and supporting CONSORT checklist are available as supplementary files (see Supplementary files 1 and 2).

Ethics statement

The Research Ethics Committee of each participating center approved the study protocol. All patients enrolled in this study provided a written informed consent. This study was conducted according to the principles expressed in the Declaration of Helsinki.

Study design

The Epzicom-Truvada study is a phase 4, multicenter, randomized, open-label, parallel group pilot study conducted in Japan that compared the efficacy and safety of a fixed dose of ABC/3TC and TDF/FTC, both combined with ritonavir-boosted atazanavir (ATV/r) for the initial treatment of HIV-1 infection for 96 weeks. Enrollment of patients began in November 2007 and ended in March 2010, and the follow-up period ended in February 2012. With a one to one ratio, the patients were randomly assigned to receive either a fixed dose of ABC/3TC or TDF/FTC, both administered with ATV/r. The randomization was stratified according to each participating site and conducted at the data center with

independent clinical research coordinators using a computer-generated randomization list prepared by a statistician with no clinical involvement in the trial.

Study patients

This study population included treatment-naïve Japanese patients aged 20 or over with HIV-1 infection who met the eligibility criteria for the commencement of antiretroviral therapy according to the DHHS Guidelines in place in the U.S. at the time of the writing of the study protocol (a CD4 count <350/μL or a history of AIDS-defining illness regardless of the CD4 count) (23). Patients were screened and excluded if they had previously taken lamivudine, tested positive for hepatitis B surface antigens, had comorbidities such as hemophilia or diabetes mellitus that required medical treatment, congestive heart failure or cardiac myopathy or if they were considered not suitable for enrollment by the attending physicians. Candidates were also excluded if their alanine aminotransferase level was 2.5 times greater than the upper limit of normal, they had an estimated glomerular filtration rate (eGFR) calculated using the Cockcroft-Gault equation of <60 mL/min, {creatinine clearance = [(140- age) × weight (kg)]/(serum creatinine ×72)(×0.85 for females)} or a serum phosphate level <2 mg/dL or had active opportunistic diseases that required treatment (24). Each patient's actual body weight was used for the calculation of eGFR. At screening, a genotypic drug resistant test and screening for the HLA-B*5701 allele were permitted but not required because the prevalence of both the drug resistant virus and the HLA-B*5701 allele are low in Japanese patients (7, 25). Medical history, including a history of AIDS-defining illnesses and other comorbidities, was also collected. Enrollment stopped on March 3, 2008 due to the recommendation from the DSMB of the trial based on the interim analysis of the ACTG5202 that ABC/3TC is less effective than TDF/FTC in patients with a baseline viral load >100,000 copies/mL (3). Accordingly, the DSMB recommended that the trial should be restarted with modified inclusion criteria: to enroll patients with an HIV-1 viral load of <100,000 copies/mL at screening, and the enrollment restarted from April 1, 2008.

Study procedures

Required visits for participants for clinical and laboratory assessments were at screening, enrollment and every 4 weeks until the viral load diminished to <50 copies/mL. For patients with a viral load <50 copies/mL, the required visit interval was every 12 weeks for the duration of the study. The evaluation performed at each visit included a physical examination, CD4 cell count, HIV-1 RNA viral load, a complete blood cell count and blood chemistries (total bilirubin, alanine aminotransferase, lactate dehydrogenase, serum creatinine, potassium, phosphate, triglycerides and low-density lipoprotein (LDL) cholesterol) and a urine examination of the levels of phosphate, creatinine and β2 microglobulin. The values of urinary β2 microglobulin were expressed relative to a urinary creatinine level of 1 g/L (/g Cr). The percent tubular resorption of phosphate was calculated using the following formula: {1-[(urine phosphate × serum creatinine)/(urine creatinine × serum phosphate)]} ×100 (26). All data, including the HIV-1 RNA viral load, were collected at each participating site and sent to the data center. Grade 3 or 4 serious adverse events were reported to the DSMB, which made a judgment whether they were caused by the study drugs. Independent research coordinators at the data center visited at least 10 facilities every year to monitor the accuracy of the submitted data and compliance to the study protocol. All authors vouch for the completeness and accuracy of the reported data.

Statistical analysis

The sample size calculation was originally conducted as follows: Assuming a 90% success rate in the TDF/FTC arm at week 48, a sample size of 224 patients (112 patients per arm) provided 80% power (one sided, α=0.05) to establish non-inferiority of ABC/3TC to TDF/FTC each in combination with ATV/r. Non-inferiority was defined as the lower bound of the two-sided 95% confidence interval (CI) with the treatment difference being above -10%. Based on this assumption, the targeted sample size was set to 240 patients (120 in each arm). However, as previously described, due to the shortage of accrued subjects, this study was underpowered and conducted as a pilot trial.

The primary efficacy endpoint was the time from randomization to virologic failure (defined as a confirmed HIV-1 RNA >1,000 copies/mL at or after 16 weeks and before 24 weeks or >200 copies/mL at or after 24 weeks) (3). The secondary efficacy endpoints included the time from randomization to either virologic failure or ART modification and a comparison of the proportions of patients with HIV-1 RNA <50 copies/mL at weeks 48 and 96 regardless of previous virologic failure. The intent-to-treat (ITT) population comprising all randomized subjects was used to assess the efficacy data; however, a comparison of the proportion of virologically-suppressed patients was conducted with both the ITT and a per protocol population while on the initial randomized regimen.

The safety endpoint was the time from randomization to the first occurrence of grade 3 or 4 laboratory data or abnormal symptoms that were at least one grade higher than the baseline. Isolated hyperbilirubinemia was excluded from the safety endpoints. The grade of adverse events was classified according to the Division of AIDS Table for grading the severity of adult and pediatric events, version 2004 (27). The tolerability endpoint was the time from randomization to any regimen modification. The safety and tolerability endpoints were calculated in the ITT population. Changes per protocol in the CD4 cell count, lipid markers and renal tubular markers at weeks 48 and 96 were compared using the Mann-Whitney test. A repeated measures mixed model was used to estimate and compare changes in the renal function between the two arms (17). The renal function was calculated using the Modification of Diet in Renal Disease study



Figure 1. Enrollment, randomization and disposition of patients.

Table 1. Demographic and Baseline Characteristics

	ABC/3TC (n=54)	TDF/FTC (n=55)	Total (n=109)
Sex (male), n (%)	53 (98.1)	54 (98.2)	107 (98.2)
Age (years)†	39 (28.8-44)	35 (29-42)	36 (29-42.5)
CD4 count (/μL)†	236.5 (194-301.3)	269 (177-306)	257 (194-305)
HIV RNA viral load (log_{10}/mL)†	4.29 (3.92-4.67)	4.28 (3.86-4.60)	4.28 (3.89-4.67)
HIV RNA viral load >100,000 log_{10}/mL, n (%)	1 (1.9)	0 (0)	1 (0.9%)
Route of transmission (homosexual contact), n (%)	47 (87)	49 (89.1)	96 (88.1)
History of AIDS n (%)	1 (1.9)	5 (9.1)	6 (5.5)
Body weight (kg)†	64 (59-72.1)	63.1 (58-69)	64 (58.3-70.7)
Body mass index (kg/m^2)†	22.6 (20.4-24.2)	21.9 (20.3-23.6)	22.4 (20.3-23.7)
eGFR (mL/min/1.73 m^2)†	96.9 (82.7-107.3)	94.4 (83.6-105.7)	96.7 (83.0-106.7)
Creatinine clearance (mL/min)†	119.3 (105.4-136.6)	124.6 (103-139.3)	120.3 (104.7-138.3)
Serum creatinine (mg/dL)†	0.76 (0.67-0.83)	0.75 (0.68-0.84)	0.76 (0.68-0.83)
Urinary β2 microglobulin (μg/g Cre)†	195.8 (98.3-505.3)	138.4 (86.8-426.4)	172.9 (88.3-458.7)
Tubular resorption of phosphate (%)†	92.9 (90-95.1)	92.3 (87.7-95.2)	92.7 (89.3-95.1)
LDL-cholesterol (mg/dL)†	91.5 (75-125.5)	94 (72.5-111.5)	94 (74.5-114)
Triglycerides (mg/dL)†	132 (98-170.5)	114 (73-184)	127 (85.5-175)
Hypertension, n (%)	3 (5.6)	1 (1.8)	4 (3.7)
Diabetes mellitus, n (%)	0 (0)	0 (0)	0 (0)
Concurrent use of nephrotoxic drugs, n (%)	10 (18.5)	10 (18.2)	20 (18.3)
Hepatitis C, n (%)	0 (0)	0 (0)	0 (0)

†median (interquartile range)

IQR: interquartile range, AIDS: acquired immunodeficiency syndrome, eGFR: estimated glomerular filtration rate, LDL: low-density lipoprotein

equation adjusted for the Japanese population (28), and a sensitivity analysis was conducted using the above mentioned Cockcroft-Gault equation.

Time-to-event distributions were estimated using the Kaplan-Meier method and compared using the two-sided log-rank test. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using the Cox proportional hazards model. For grade 3 or 4 serious adverse events caused by the study drugs, the description and severities were recorded. Statistical significance was defined at two-sided p values <0.05. All statistical analyses were performed with The Statistical Package for Social Sciences ver. 17.0 (SPSS, Chicago, IL).

Results

Patient disposition and baseline characteristics

109 patients from 18 centers were enrolled and randomized between November 2007 and March 2010. Of these patients, 54 and 55 were allocated to the ABC/3TC and TDF/FTC arms, respectively (Fig. 1). The baseline demographics and characteristics are shown in Table 1. Most patients were men, with a median body weight of 64 kg. The median CD4 cell count was 257/μL (IQR: 194-305). One patient in the ABC/3TC arm had a baseline HIV-1 RNA level of >100,000



Figure 2. Efficacy results over 96 weeks. (A) Time to protocol-defined virologic failure. (B) Time to the first occurrence of either virologic failure or discontinuation of the initially randomized regimen. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine



Figure 3. Efficacy results at 48 and 96 weeks. Proportion of patients with an HIV RNA level <50 copies/mL regardless of previous virologic failure with 95% binomial confidence intervals at 48 and 96 weeks. (A) Intention-to-treat analysis. (B) Per protocol analysis. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine

copies/mL. This patient was enrolled before the announcement of the interim analysis of ACTG5202 in March 2008 and achieved an HIV-1 RNA level of <50 copies/mL by the end of that month. One patient in the TDF/FTC arm had a history of lamivudine use. That patient was included in the analysis because this aspect of the medical history was identified after randomization and initiation of the allocated treatment.

Efficacy results

In the primary efficacy analysis, the time to virologic failure was not significantly different in the ABC/3TC arm from that observed in the TDF/FTC arm by 96 weeks (HR, 2.09; 95% CI, 0.72-6.13; p=0.178). Virologic failure occurred in 5 and 10 patients in the ABC/3TC and TDF/FTC arms, respectively (Fig. 2A). In the secondary efficacy analysis, the times to the first occurrence of confirmed virologic failure or discontinuation of the initially allocated regimen were not different between the two arms (HR, 1.30; 95% CI, 0.61-2.77; p=0.502) (Fig. 2B). Among the ITT population, the proportion of patients with an HIV RNA level <50 copies/mL at week 48 regardless of previous virologic failure was 81.5% in the ABC/3TC group and 80% in the TDF/FTC group, for a difference of -1.5% (95% CI, -16% to 13%), and at week 96, 72.2% and 78.2% for the ABC/3TC and TDF/FTC groups, respectively, for a difference of 6% (95% CI, -10% to 22%) (Fig. 3A). The per protocol analysis showed that the proportions at week 48 were 91.7% and 86.3% for the ABC/3TC and TDF/FTC groups, respectively, for a difference of -5.4% (95% CI, -18% to 7%). At week 96, the proportions were 88.6% and 95.6% for the ABC/3TC and TDF/FTC groups, respectively, for a



Figure 4. Safety and tolerability results over 96 weeks. (A) Time to first primary safety endpoint, defined as the first grade 3 or 4 event on the initial randomized regimen, which was at least one grade higher than baseline. (B) Time to tolerability endpoint, defined as the first change in regimen. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine

Table 2. Selected Grade 3 or 4 Events While Receiving Randomized Antiretroviral Drugs

	ABC/3TC (n=54)	TDF/FTC (n=55)	Total (n=109)
Overall, n (%)	13 (24)	10 (18)	23 (21)
Laboratory, n (%)	12 (22)	7 (13)	19 (17)
Alanine aminotransferase, n	0	1	1
LDL-cholesterol, n	6	2	8
Triglycerides, n	0	3	3
Uric acid, n	1	0	1
Serum phosphate, n	2	0	2
Serum calcium, n	1	0	1
Serum creatinine, n	1	0	1
Platelets count, n	1	1	2
Symptoms, n (%)	1 (2)	3 (5)	4 (4)
Depression, n	0	2	2
Fever, n	1	1	2

More than one event occurred in 2 patients.
LDL: low-density lipoprotein

difference of 6.9% (95% CI, -4.2% to 18%) (Fig. 3B). The primary and secondary efficacy analyses did not show a significant difference in viral efficacy between the two arms.

Safety and tolerability results

10 (18.5%) and 7 (12.7%) patients in the ABC/3TC and TDF/FTC groups, respectively, experienced 23 grade 3 or 4 adverse events related to the study drugs while on the initial regimen. The time to the first adverse event was not significantly different between the two arms (HR 0.66; 95% CI, 0.25-1.75, p=0.407) (Fig. 4A). Table 2 shows a list of selected grade 3 or 4 safety events. Among the adverse events, 48% included elevation of lipid markers. The tolerability endpoint, the time to first ART modification, was not significantly different between the two arms (HR 1.03; 95% CI, 0.33-3.19, p=0.964), and only 6 (11.1%) and 6 (10.9%) patients in the ABC/3TC and TDF/FTC arms, respectively, discontinued the initially allocated regimen by 96 weeks (Fig. 4B). The most common reason for regimen modification was drug toxicity (n=10; 4 in ABC/3TC and 6 in TDF/FTC arm; suspected ABC hypersensitivity reactions based on the appearance of rash and fever in HLA-B*5701-negative patient; n=1, depression; n=3, jaundice; n=3, nausea; n=2, and lipodystrophy; n=1). One patient in the ABC/3TC group developed a cerebral infarction during week 39 but was able to continue the study drugs. No deaths were registered during the study period.

Changes in the CD4 cell count and other parameters of interest

The increase in the median CD4 count from baseline to 48 weeks was marginally larger in the ABC/3TC arm than in the TDF/FTC arm (median: ABC/3TC: 216, TDF/FTC: 192, p=0.107). This difference was significantly larger at 96

Table 3. **Median Values of Changes in Parameters of Interest from Baseline to 96 Weeks**

	ABC/3TC (n=54)				TDF/FTC (n=55)				
	Number tested (baseline, week 96)	Baseline	Week 96	Median Δ	Number tested (baseline, week 96)	Baseline	Week 96	Median Δ	p value
CD4 cell count (/μL)	54, 43	236.5	545	328	55, 45	269	493	216	0.031
Lipids									
LDL-cholesterol (mg/dL)	54, 16	91.5	149	31.5	53, 16	94	97	2	0.026
Triglyceride (mg/dL)	54, 29	132	257	111	55, 26	114	202	40.5	0.037
Renal tubular markers									
Urinary β2 microglobulin (μg/g Cre)	49, 32	195.8	99.2	-94.9	52, 38	138.4	303.9	86.6	<0.001
Tubular resorption of phosphate (%)	49, 32	93	92	-1.4	50, 36	92	91	-2.6	0.930

LDL: low-density lipoprotein



Figure 5. **Changes in the renal function between baseline and 96 weeks. (A) Changes in the estimated glomerular filtration rate calculated with the Modification of Diet in Renal Disease study equation adjusted for the Japanese population. (B) Changes in creatinine clearance calculated with the Cockcroft-Gault equation. The data are presented as the mean±95% confidence interval. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine**

weeks (ABC/3TC: 328, TDF/FTC: 236, p=0.031, Table 3). The increases in both LDL-cholesterol and triglycerides from baseline to 96 weeks were more significant in the ABC/3TC arm than in the TDF/FTC arm. One patient in the TDF/FTC arm had been treated with lipid-lowering medications prior to study enrollment. Furthermore, 7 patients and 1 patient in the ABC/3TC and TDF/FTC arms, respectively, started lipid-lowering agents during the study period. With regard to renal tubular markers, the levels of urinary β2 microglobulin increased in the TDF/FTC arm (median: 86.6 μg/g Cre), whereas it decreased in the ABC/3TC arm (median: -94.9 μg/g Cre). These changes were significantly different between the two arms (p<0.001). On the other hand, tubular resorption of phosphate did not show changes from baseline to 96 weeks in the two groups, and the levels were not different between the two arms (Table 3).

Changes in the renal function

A data analysis using repeated measures mixed models showed a significant decrease in the mean eGFR from baseline to 96 weeks in both groups (ABC/3TC: -8.7 mL/min/1.73 m^2, 95%CI -13.3 to -4.2, p<0.001; TDF/FTC: -9.2 mL/min/1.73 m^2, 95%CI -13.7 to -4.7, p<0.001) (Fig. 5A). There was no significant interaction between the trend of the two arms over time (p=0.202), thus indicating that the change in eGFR from baseline to 96 weeks was not significantly different between the two arms. A sensitivity analysis of creatinine clearance calculated using the Cockcroft-Gault equation showed that creatinine clearance decreased significantly from the baseline in the TDF/FTC arm (-9.6 mL/min, 95%CI -16.6 to -2.5, p<0.001) but not in the ABC/3TC arm (-4.1 mL/min, 95%CI -11.2 to 3.0, p=0.466)(Fig. 5B). No significant interaction between the trend of the two arms was observed with respect to creatinine clearance (p=0.403). Two patients in the ABC/3TC arm progressed to more advanced chronic kidney disease (CKD) stage by the last per protocol visit: one patient progressed to stage 4 CKD (eGFR <30 mL/min/1.73 m^2) and the other to stage 3 CKD (eGFR <60 mL/min/1.73 m^2). However, ABC/3TC did not appear to be the causative drug for renal dysfunction in these two cases because the deterioration in the renal function was associated with the development of malignant lymphoma in the former patient and with the commencement of fenofibrate treatment in the latter; renal function recovered rapidly in the latter patient after the discontinuation of fenofibrate.

Discussion

Although insufficiently powered to show the non-inferiority of the viral efficacy of ABC/3TC relative to TDF/

FTC, this pilot study is the first randomized study conducted in Asia to elucidate the efficacy and safety of fixed doses of these two regimens each administered in combination with ATV/r for initial HIV-1 therapy. Viral efficacy, safety, and tolerability were not significantly different in the two arms of Japanese patients with a baseline HIV viral load <100,000 copies/mL over 96 weeks. Both regimens showed favorable viral efficacy, as in the ITT population, 72.2% and 78.2% of the patients in the ABC/3TC and TDF/FTC arms, respectively, had HIV-1 viral loads of <50 copies/mL at 96 weeks. Both regimens were also well-tolerated, as only 11.1% and 10.9% of the patients in the ABC/3TC and TDF/FTC arms, respectively, discontinued the allocated regimen by 96 weeks. Clinically suspected (not immunologically-confirmed) ABC-associated hypersensitivity reaction occurred in only one (1.9%) patient in the ABC/3TC arm, confirming that ABC hypersensitivity is rare in populations in which HLA-B*5701-positive patients are uncommon. Thus, this trial suggests that ABC/3TC may be an efficacious and safe regimen for use in HLA-B*5701-negative populations, such as the Japanese, with a baseline HIV viral load <100,000 copies/mL.

The usefulness of ABC/3TC has recently received higher recognition for two reasons. One, a meta-analysis by the FDA did not confirm the association between ABC use and myocardial infarction (9). Two, it became clear that TDF-induced renal tubulopathy results in decreased bone mineral density due to phosphate wasting and a decreased renal function, both of which might develop into serious complications with long-term TDF use (12-14, 29, 30). On the other hand, greater deteriorations in the levels of lipid markers were noted in ABC/3TC than in TDF/FTC in clinical trials comparing these two agents (16, 17). The present study also demonstrated that the increases in the LDL-cholesterol and triglyceride levels were higher in the ABC/3TC arm than in the TDF/FTC arm.

TDF-induced nephrotoxicity is of particular interest in this study because a low body weight is an important risk factor, and body stature was much smaller in this study population (median baseline body weight 64 kg), than in the ASSERT study (72 kg), which compared the renal function between patients receiving ABC/3TC and TDF/FTC with efavirenz in Europe (17, 18, 20). This study showed that changes in the renal function from baseline were not significantly different between the two arms, similar to the findings of the ASSERT study. None of the patients in the TDF/FTC arm exhibited progression of CKD stage. On the other hand, the levels of urinary β2 microglobulin deteriorated significantly from baseline in the TDF/FTC arm, whereas improvements were observed in the ABC/3TC arm. This is also similar to the findings reported by the ASSERT trial. This suggests that urinary β2 microglobulin is a more sensitive marker for evaluating TDF nephrotoxicity than the renal function calculated by serum creatinine, as also demonstrated in our previous work (31). Tubular resorption of phosphate, another marker examined to evaluate the renal tubular function, did not exhibit any changes from baseline or between the two arms, suggesting that urinary β2 microglobulin may be a better marker for evaluating TDF nephrotoxicity than tubular resorption of phosphate. Of note, in both arms, the renal function did significantly decrease from baseline. To our knowledge, this is the first randomized trial comparing ABC/3TC and TDF/FTC that observed deterioration of the renal function after the initiation of ART. This result highlights the importance of regular monitoring of renal function after initiation of ART, although it is difficult to draw a firm conclusion on the prognosis of the renal function from this study, due to the limited length of the observation period and the small number of enrolled patients.

Only one patient (1.9%) in the ABC/3TC arm developed a clinically suspected ABC-associated hypersensitivity reaction, which was diagnosed based on the appearance of a skin rash and fever six weeks after commencement of the study drug. The patient fully recovered after discontinuation of the drugs. The ASSERT trial of HLA-B*5701-negative patients reported a similar incidence (3%) of clinically suspected ABC hypersensitivity reactions (17). The one case observed in our trial could be a false positive, because ABC hypersensitivity reactions commonly occur 9-11 days after the initiation of therapy (32), and ABC hypersensitivity was not confirmed immunologically. Nonetheless, immediate discontinuation of ABC is highly recommended even in HLA-B*5701-negative patients suspected of ABC hypersensitivity, since ABC hypersensitivity can occur in such patients (33) and errors in genotyping for HLA or reporting a genotype might occur in practice (34).

Several limitations of this trial should be acknowledged. First, due to the shortage of enrolled patients, the trial was insufficiently powered to test non-inferiority of the viral efficacy of ABC/3TC against TDF/FTC, as initially planned. However, the safety and tolerability data of these regimens in Asia are a valuable asset for patients from this region, and efficacy data could be utilized as part of a meta-analysis in the future. Second, the enrolled subjects were mostly men (primarily men who had sex with men and very few injection drug users). Further studies are needed to examine the efficacy and safety of these regimens in women and patients with different routes of transmissions in Asia.

In summary, this randomized trial demonstrated high efficacy and safety of fixed-dose ABC/3TC and TDF/FTC in combination with ATV/r over 96 weeks for treatment-naïve Japanese patients with a baseline HIV-1 viral load <100,000 copies/mL, although it was insufficiently powered to show non-inferiority of the viral efficacy of ABC/3TC compared with TDF/FTC. ABC/3TC with ATV/r is a safe and efficacious initial regimen for treating HLA-B*5701-negative patients with a baseline HIV-1 viral load <100,000 copies/mL.

Author's disclosure of potential Conflicts of Interest (COI).
Uchiumi H: Research funding, ViiV Healthcare. Koibuchi T: Research funding, Nihon Ultmarc Inc. Naito T: Research funding,

MSD K.K. and Janssen Pharmaceutical K.K. Takada K: Research funding, ViiV Healthcare. Oka S: Research funding, MSD K.K., Abbott Japan, Co., Janssen Pharmaceutical K.K., Pfizer, Co., and Roche Diagnostics K.K.

Authors' contributions

SO, MT (Takano), MI, HG, YK and YT designed the study. TE, MH, SK, HU, TK, TN (Naito), MY (Yoshida), NT, MU, YY, TF, SH, KT, MY (Yamamoto), SM, MT (Tateyama) and YT collected the data. HM supervised the study and reviewed and approved study report. TN (Nishijima), HK, HG and SO analyzed and interpreted the data. TN (Nishijima), HK, HG and SO drafted the manuscript and all other authors revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgement

We thank the patients for participating in this study. The authors are indebted to Mikiko Ogata and Akiko Nakano for their support in this study as a data manager and research coordinator, respectively. The Epzicom-Truvada study team includes the following members: Takao Koike[1], Mitsufumi Nishio[1], Keisuke Yamaguchi[1], Katsuya Fujimoto[1], Satoshi Yamamoto[1], Ikumi Kasahara[1], Tetsuro Takeda[2], Takafumi Tezuka[2], Hiroshi Moro[2], Takeharu Kotani[3], Mieko Yamada[3], Yoshiyuki Ogawa[4], Kunio Yanagisawa[4], Aikichi Iwamoto[5], Takeshi Fujii[5], Takashi Odawara[5], Nahoko Miyazaki[5], Kazufumi Matsumoto[5], Kumiko Sumino[5], Mizue Saita[6], Mai Suzuki[6], Rino Sakamoto[6], Satoshi Kimura[7], Yukihiro Yoshimura[8], Motohiro Hamaguchi[9], Naoto Mamiya[9], Atsuyoshi Imamura[9], Ayumi Kogure[9], Mayumi Imahashi[9], Takuma Shirasaka[10], Munehiro Yoshino[10], Sawada Akihiro[11], Tazuko Tokugawa[11], Seiji Saito[12], Noboru Takata[12], Fumiko Kagiura[12], Rumi Minami[13], Soichiro Takahama[13], Toshikazu Miyagawa[14], Daisuke Tasato[15], Hideta Nakamura[15], Naoki Ishizuka[16], Katsuji Teruya[16], Miwako Honda[16], Kunihisa Tsukada[16], Hirohisa Yazaki[16], Junko Tanuma[16], Haruhito Honda[16], Ei Kinai[16], Koji Watanabe[16], Takahiro Aoki[16], Tamayo Watanabe[16], Mahoko Kamimura[16], Masako Ito[16], Jiro Mikami[16], Atsushi Kubota[16], Toshikatsu Kawasaki[16]

[1]Hokkaido University Hospital, Japan; [2]Niigata University Medical and Dental Hospital, Japan; [3]Ishikawa Prefectural Central Hospital, Japan; [4]Gunma University Graduate School of Medicine, Japan; [5]Research Hospital of the Institute of Medical Science, The University of Tokyo, Japan; [6]Juntendo University School of Medicine, Japan; [7]Tokyo Teishin Hospital, Japan; [8]Yokohama Municipal Citizen's Hospital, Japan; [9]National Hospital Organization Nagoya Medical Center, Japan; [10]National Hospital Organization Osaka Medical Center, Japan; [11]Hyogo College of Medicine, Japan; [12]Hiroshima University Hospital, Japan; [13]National Hospital Organization Kyushu Medical Center, Japan; [14]Kumamoto University Graduate School of Medical Sciences, Japan; [15]University of the Ryukyus, Okinawa, Japan and [16]National Center for Global Health and Medicine, Japan.

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [http : / / www. aidsinfo. nih. gov / contentfiles / lvguidelines / adultandadolescentgl.pdf].
2. European AIDS Clinical Society Guidelines version 6 [http://www.europeanaidsclinicalsociety. org / images / stories / EACS-Pdf / EACSGuidelines-v6.0-English.pdf].
3. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med **361**: 2230-2240, 2009.
4. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS **23**: 1547-1556, 2009.
5. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther **23**: 1603-1614, 2001.
6. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med **358**: 568-579, 2008.
7. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics **9**: 207-214, 2008.
8. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet **371**: 1417-1426, 2008.
9. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr **61**: 441-447, 2012.
10. Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr **35**: 269-273, 2004.
11. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis **40**: 1331-1333, 2002.
12. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS **22**: 2155-2163, 2008.
13. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis **51**: 496-505, 2010.
14. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis **203**: 1791-1801, 2011.
15. Guidelines for antiretroviral therapy. Japanese Ministry of Health and Welfare, in Japanese. [http://www.haart-support.jp/pdf/guideline2012.pdf].
16. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis **204**: 1191-1201, 2011.
17. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr **55**: 49-57, 2010.
18. Nishijima T, Gatanaga H, Komatsu H, et al. Renal function de-

clines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One **7**: e29977, 2012.

19. Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res **8**: 504-509, 2010.

20. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS **21**: 1273-1281, 2007.

21. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One **6**: e22661, 2011.

22. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ **340**: c869, 2010.

23. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents October 10, 2006. [http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000629.pdf].

24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron **16**: 31-41, 1976.

25. Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res **88**: 72-79, 2010.

26. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis **48**: e108-e116, 2009.

27. DIVISION OF AIDS TABLE FOR GRADING THE SEVERITY OF ADULT AND PEDIATRIC ADVERSE EVENTS VERSION 1.0, DECEMBER, 2004; CLARIFICATION AUGUST 2009. [http://www.mtnstopshiv.org/sites/default/files/attachments/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf].

28. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis **53**: 982-992, 2009.

29. Kudo K, Konta T, Mashima Y, et al. The association between renal tubular damage and rapid renal deterioration in the Japanese population: the Takahata study. Clin Exp Nephrol **15**: 235-241, 2011.

30. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant **26**: 3224-3229, 2011.

31. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary β_2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses **22**: 744-748, 2006.

32. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis **43**: 103-105, 2006.

33. Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother **60**: 599-604, 2007.

34. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther **91**: 734-738, 2012.

Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection

Hiroyuki Gatanaga,[1,2] Tsunefusa Hayashida,[1,2] Junko Tanuma,[1] and Shinichi Oka[1,2]

[1]AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, and [2]Center for AIDS Research, Kumamoto University, Japan

Background. Hepatitis B virus (HBV) infection is common in individuals infected with human immunodeficiency virus, especially in men who have sex with men (MSM). Almost all currently used regimens of antiretroviral therapy (ART) contain lamivudine (LAM) or tenofovir disoproxil fumarate (TDF), both of which have significant anti-HBV activity. However, the prophylactic effect of ART on HBV infection has not been assessed previously.

Methods. Non-HBV-vaccinated HIV-infected MSM were serologically evaluated for HBV infection using stocked serum samples. Cases negative for HBV surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to HBV core antigen (anti-HBc) in first serum samples were serologically followed until last available stocked samples. HBV genotype and LAM-resistant mutation (rtM204V/I) were analyzed in cases that became HBsAg-positive.

Results. The first stocked samples were negative for all analyzed HBV serological markers in 354 of 1434 evaluated patients. The analysis of their last samples indicated HBV incident infection in 43 of them during the follow-up period. The rate of incident infections was lower during LAM- or TDF-containing ART (0.669 incident infections in 100 person-years) than during no ART period (6.726 incident infections in 100 person-years) and other ART (5.263 incident infections in 100 person-years) ($P < .001$). Genotype A was most prevalent (76.5%), and LAM-resistant HBV was more frequent in incident infections during LAM-containing ART (50.0%) than in those during no ART and other ART (7.1%) ($P = .029$).

Conclusions. LAM- and TDF-containing ART regimens seem to provide prophylaxis against HBV infection, although drug-resistant strains seem to evade these effects.

Keywords. lamivudine; tenofovir disoproxil fumarate; resistant; chronic infection.

Patients with human immunodeficiency virus (HIV) infection are at high risk for both hepatitis B virus (HBV) infection and development of chronic infection [1–4]. Based on information from Western countries, the rate of coinfection varies according to risk categories; the highest rate is in men who have sex with men (MSM), with a slightly lower rate among intravenous drug users, and much lower in individuals infected through heterosexual contacts [5–8]. In Japan, HIV/HBV coinfection is also significantly associated with MSM [9, 10]. The progression of chronic HBV infection to cirrhosis, end-stage liver diseases, and/or hepatocellular carcinoma is more rapid in HIV-infected persons than in those with chronic HBV infection alone [11, 12]. Vaccination of non-HBV-immunized HIV-infected individuals is recommended to prevent HBV infection [13]. However, all current recommended antiretroviral therapy (ART) regimens contain lamivudine (LAM) or tenofovir disoproxil fumarate (TDF), both of which have significant anti-HBV activity [14]. Do these ART regimens provide any prophylaxis against HBV infection? This is an important question, as a positive answer could influence the strategy applied to prevent HBV infection in HIV-infected individuals. To delineate the hepatitis B prophylactic effect of ART, we used stocked samples for serological evaluation of HBV infection in HIV-infected MSM. The present

Received 6 November 2012; accepted 25 February 2013; electronically published 13 March 2013.

Correspondence: Hiroyuki Gatanaga, MD, AIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan (higatana@acc.ncgm.go.jp).

Clinical Infectious Diseases 2013;56(12):1812–9

DOI: 10.1093/cid/cit145

study included those patients who had tested negative for hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) using their first stocked blood samples, who were followed up serologically to identify new HBV incident infections among them. The other part of the study covered analysis of the relation between the frequency of incident infection and ART regimens.

METHODS

Patients

Since April 1997, we have stocked serum samples taken at routine clinical practice from HIV type 1 (HIV-1)–infected patients who visited the Outpatient Clinic of the AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, under signed informed consent for use in virologic research. Every patient had been interviewed at the first visit by clinical nurse specialists at the HIV outpatient clinic using a structured questionnaire that includes items on sexuality and history of HBV vaccination. Most of the patients regularly visited our clinic every 1–3 months, and we had collected and stored their sera at almost all visits. The ethics committee of the National Center for Global Health and Medicine approved the collection and analysis of the samples. First, we selected HIV-1–infected MSM who met the following inclusion criteria: (1) the first visit to our clinic was between April 1997 and December 2009, (2) they had not received HBV vaccination before the first visit, and (3) at least 2 serum samples were available and collected at least 6 months apart. The first sample was defined as the baseline serum sample, and baseline clinical data were defined as those recorded on the date of sampling of the first stocked serum. Patients' baseline characteristics, including age, race, hepatitis C virus antibody, results of *Treponema pallidum* hemagglutination assay, and $CD4^+$ cell count were collected from the medical records.

HBV Analysis

In order to identify new HBV incident infection, we excluded patients with previously confirmed HBV infection. The baseline samples of the patients who met the inclusion criteria described above were serologically evaluated for HBsAg, anti-HBs, and anti-HBc using ARCHITECT HBsAg QT assay, anti-HBs assay, and anti-HBc assay, respectively (Abbott Laboratories, Chicago, Illinois) [15, 16]. Patients positive for any of HBsAg, anti-HBs, and anti-HBc at baseline were excluded from the serological follow-up. The remaining patients were considered to have never been infected with HBV before the baseline. Their last stocked sample taken before or in December 2010, or before HBV vaccination if performed during the follow-up period, was analyzed for HBsAg, anti-HBs, and anti-HBc. If the last sample was negative for all 3, the patient was considered to have never been infected with HBV up to the sampling date of the last stocked serum. If HBsAg, anti-HBs, or anti-HBc was positive in the last stocked serum, the patient was considered to have HBV incident infection during the follow-up period. In the latter case, the baseline samples were subjected to polymerase chain reaction (PCR) analysis for HBV DNA [17, 18], and all the stocked samples during the follow-up period were serologically analyzed to determine the date of HBV incident infection. The date of incident infection was defined as the sampling date of the first positive serum for any HBV serological marker. The time from the baseline to HBV incident infection was analyzed by the Kaplan-Meier method. The data were censored at the sampling date of the last stocked sample if it was negative for all analyzed HBV serological markers. Patients' age and $CD4^+$ cell count at the date of incident infection and alanine aminotransferase (ALT) values within 3 months of incident infection were collected. If an HBsAg-positive sample was available, HBV genotype and LAM-resistant mutation (rtM204V/I) were analyzed by PCR-invader assay [17–19]. The diagnosis of chronic HBV infection was considered when HBsAg was still positive in sera taken at 6 months or longer after the incident infection.

Antiretroviral Therapy

To determine the type of ART under which HBV incident infection occurred, the regimen information of ART was collected from medical records over the period spanning from the baseline to the incidence infection or to the end of follow-up. The treatment status was divided into 4 categories: (1) No ART, no treatment with any antiretroviral agent; (2) Other-ART, ART with regimens that did not contain LAM, TDF, or emtricitabine (FTC); (3) LAM-ART, ART with LAM-containing regimens that did not contain TDF or FTC; and (4) TDF-ART, ART with TDF-containing regimens with or without LAM or FTC. Data were censored on the sampling date of the last stocked sample if it was negative for all analyzed HBV serological markers. When the treatment category was modified, the data were censored on the date of category change for the previous treatment category and a new follow-up as a different case was initiated for the replacement treatment category.

Statistical Analysis

The time from the baseline to HBV incident infection was analyzed by the Kaplan-Meier method. The Cox proportional hazards regression analysis was used to assess the risk of HBV incident infections. The impact of patients' baseline characteristics, year of entry, the use of antiretroviral agents (any antiretroviral, and any of LAM, TDF, or FTC), and the frequency of changing ART regimen during the follow-up period was estimated with univariate analysis, and those with statistical significance were incorporated into multivariate analysis. The



Figure 1. Patient selection process: 1434 patients met the inclusion criteria. Of these patients, 1080 were excluded because of positive hepatitis B virus serology in the first samples. The results of various serological tests are shown. The remaining 354 were enrolled for serological follow-up. Of these, 43 were positive in the last sample analysis. Their stocked samples were analyzed serologically and the results of HBV serology using the first positive samples are indicated. Abbreviations: anti-HBc, antibody to HBV core antigen; anti-HBs, antibody to HBsAg; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; MSM, men who have sex with men.

frequency and risk of HBV incident infection during each treatment category was also assessed by univariate Cox proportional hazards regression analysis. We used hazard ratios and 95% confidence intervals to estimate the impact of each variable on incident infection. Patients' age and $CD4^+$ cell count on the date of incident infection, and peak value of ALT within 3 months of incident infection were compared between transient infection and chronic infection with Wilcoxon rank-sum test. The differences in rates of HBV genotype A and rtM204V/I mutation were compared with χ^2 test (ie, the Fisher exact test). Statistical significance of difference was defined as a 2-sided P value of <.05. All statistical analyses were performed with the Statistical Package for Social Sciences version 17.0 (SPSS, Chicago, Illinois).

RESULTS

Figure 1 shows the patient selection procedure. A total of 1434 HIV-1–infected MSM met the inclusion criteria described in the Methods section. Of these, 146 patients (10.2%) were positive for HBsAg, 737 (51.4%) were positive for anti-HBs, and 197 (13.7%) were solely positive for anti-HBc using baseline samples. The remaining 354 patients (24.7%; negative for HBsAg, anti-HBs, and anti-HBc at baseline), who were considered to have never been infected with HBV, were enrolled for serological follow-up. Table 1 lists their baseline characteristics. Serological analysis of the last sample of each of these patients showed HBV incident infection during follow-up in 43 (12.1%). Their baseline samples were found to be PCR-negative for HBV DNA, confirming that the incident infection in these patients occurred during the follow-up period. All stocked samples of the 43 patients were analyzed serologically to determine the date of HBV incident infection. HBV incident infections occurred every year between 1997 and 2010 except in 1998. The median time period from the baseline to HBV incident infection was 1.6 years (interquartile range [IQR], 192–1151 days; range, 28–4068 days). The total observation period was 1607 person-years (median, 3.7 years [IQR], 1.9–6.5 years). Figure 2 shows the Kaplan-Meier curve for the HBV incident infection for the whole cohort of enrolled patients.

In order to assess the risk of HBV incident infections, patients' baseline characteristics, year of entry, the use of any antiretroviral agents, the use of any of LAM, TDF, or FTC, and the frequency of changing ART regimen during the follow-up

Table 1. Baseline Characteristics of the 354 Enrolled Patients

Characteristic	Total (n = 354)	Year of Entry			
		1997–2000 (n = 61)	2001–2003 (n = 79)	2004–2006 (n = 112)	2007–2009 (n = 102)
Age, y, median (IQR)	32.0 (27.0–38.0)	32.0 (27.8–37.3)	31.0 (27.0–37.8)	32.0 (27.0–38.0)	35.0 (27.0–42.0)
Race/ethnicity					
Japanese	340 (96.0)	59 (96.7)	78 (98.7)	109 (97.3)	94 (92.2)
Asian other than Japanese	4 (1.1)	0 (0.0)	0 (0.0)	1 (0.9)	3 (2.9)
Caucasian	10 (2.8)	2 (3.3)	1 (1.3)	2 (1.8)	5 (4.9)
HCV antibody, positive	8 (2.3)	1 (1.6)	2 (2.5)	1 (0.9)	4 (3.9)
TPHA positive	101 (28.5)	23 (37.7)	20 (25.3)	30 (26.8)	28 (27.5)
$CD4^+$ cell count, cells/mm^3, median (IQR)	277 (151–404)	277 (169–417)	313 (97–443)	316 (176–413)	252 (129–359)
HIV RNA, log_{10} copies/mL, median (IQR)	4.6 (3.8–5.2)	4.5 (3.6–5.2)	4.8 (3.9–5.4)	4.4 (3.8–4.9)	4.7 (3.9–5.2)

Data are No. (%) unless otherwise specified.

Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; TPHA, *Treponema pallidum* hemagglutination assay.



Figure 2. Kaplan-Meier curve showing the time to hepatitis B virus incident infection.

period were estimated using a proportional hazards model (Table 2). Younger age and higher $CD4^+$ cell count correlated positively, and use of any antiretroviral, use of LAM, TDF, or FTC, and the frequency of changing ART regimen correlated negatively with HBV incident infection, with statistical significance in univariate analysis. However, in multivariate analysis, the use of LAM, TDF, or FTC continued to show significant relation. Then, we focused on the relation between treatment status and HBV incident infection. The observation period in each patient was divided into 4 categories by treatment status: No ART, no treatment with any antiretroviral agent; Other-ART, ART with regimens that did not contain LAM, TDF, or FTC; LAM-ART, ART with LAM-containing regimens that did not contain TDF or FTC; or TDF-ART, ART with TDF-containing regimens with or without LAM or FTC. No participant received FTC single tablet (Emtriva). All the participants who took FTC received the combination tablet of TDF/FTC (Truvada), and therefore, such treatment status was categorized as TDF-ART. The total categorized observation period of No ART, Other-ART, LAM-ART, and TDF-ART was 446, 114, 814, and 233 person-years, respectively. The number of the HBV incident infections was 30 during the No ART period, 6 during Other-ART period, 7 during LAM-ART period, and 0 during TDF-ART period. No incident infection occurred at the time of changing ART regimen. The proportional hazards model showed a significantly lower frequency of HBV incident infection during LAM- or TDF-ART (0.669 incident infections per 100 person-years) compared with that during No ART (6.726 incident infections per 100 person-years), although there was no significant difference between Other-ART (5.263 incident infections per 100 person-years) and No ART, suggesting that ART regimens with anti-HBV activity can reduce HBV incident infections by 90% (Table 3). During LAM-ART, the HIV-1 load around the period of incident infection remained below the detection limit in all the 7 infected patients, indicating excellent adherence to ART.

Figure 3 shows peak ALT levels for the 43 HBV incident infections. Among the 36 incident infections observed the No ART and Other-ART groups, 16 infections (44.4%) were asymptomatic and not associated with significant increases in ALT (peak ALT, <60 IU/L). We were able to serologically follow 33 of the 36 cases for 6 months after the date of incident infection (TDF-ART was introduced within 6 months of incident infection in the other 3 cases). Among the 33 patients, 13 (39.4%) developed chronic infection (HBsAg was still positive 6 months after the date of incident infection). The median $CD4^+$

Table 2. Cox Proportional Hazards Regression Analysis for the Risk of Hepatitis B Virus Incident Infection

	Univariate Analysis		Multivariate Analysis	
Factors	Hazard Ratio (95% CI)	*P* Value	Hazard Ratio (95% CI)	*P* Value
Year of entry, per 1 y increase	.942 (.860–1.033)	.207		
Baseline characteristics				
Age, per 1 y increase	.921 (.879–.965)	.001	.958 (.917–1.001)	.054
Race (Japanese)	21.243 (.010–45 657.613)	.435		
HCV antibody	.048 (<.001–346.311)	.503		
TPHA	1.475 (.792–2.747)	.220		
$CD4^+$ cell count, per 100 cells/mm^3 increase	1.121 (1.008–1.246)	.035	.882 (.752–1.034)	.121
HIV RNA, per 1 log_{10} copies/mL increase	1.387 (.999–1.924)	.051		
Antiretroviral use during follow-up period				
Any antiretroviral	.097 (.052–.184)	<.001	.927 (.305–2.818)	.893
LAM, TDF, or FTC	.075 (.039–.146)	<.001	.110 (.031–.390)	.001
Frequency of changing regimen	.245 (.145–.414)	<.001	.700 (.385–1.270)	.240

Abbreviations: CI, confidence interval; FTC, emtricitabine; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LAM, lamivudine; TDF, tenofovir disoproxil fumarate; TPHA, *Treponema pallidum* hemagglutination assay.

Table 3. Frequency and Hazard Ratio of Hepatitis B Virus Incident Infection in Each Treatment Status Category

ART	Observation Period (Person-Years)	Incident Infection	Hazard Ratio (95% CI)	*P* Value
No ART	446	30	1	. . .
Other-ART	114	6	.924 (.381–2.239)	.861
ART containing at least 1 of LAM, TDF, and FTC[a]	1047	7	.113 (.049–.261)	<.001
LAM-ART	814	7		
TDF-ART	233	0		

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; FTC, emtricitabine; LAM, lamivudine; TDF, tenofovir disoproxil fumarate; LAM-ART, ART with LAM-containing regimens that did not contain TDF or FTC; Other-ART, ART with regimens that did not contain LAM, TDF, or FTC; TDF-ART, ART with TDF-containing regimens with or without LAM or FTC.

[a] No participant received FTC single tablet (Emtriva) during the observation period. All the participants who took FTC received the combination tablet of TDF/FTC (Truvada), and therefore, such treatment status was categorized into TDF-ART.



Figure 3. Peak alanine aminotransferase (ALT) values in hepatitis B virus (HBV) incident infections according to treatment regimen. Thirty, 6, and 7 HBV incident infections were observed during No antiretroviral therapy (ART), Other-ART, and lamivudine (LAM)–ART, respectively. No incident infection was identified during tenofovir disoproxil fumarate (TDF)–ART. No participant received emtricitabine (FTC) single tablet (Emtriva) during the observation period. All the participants who took FTC received the combination tablet of TDF/FTC (Truvada), and therefore, such treatment status was categorized into TDF-ART. Data are peak ALT values measured within 3 months of the date of incident infections. LAM-resistant mutation (rtM204V/I) was analyzed in 34 cases using the available hepatitis B surface antigen (HBsAg)–positive samples. Open squares: patients infected with LAM-resistant HBV. Closed circles and squares: patients who developed chronic infection (HBsAg-positive 6 months after the date of incident infection). Checked circles and squares: patients who received TDF-containing ART within 6 months of incident infection. Abbreviations: ALT, alanine aminotransferase; ART, antiretroviral therapy; LAM, lamivudine.

cell count was lower in the patients who developed chronic infection than in those with transient infection, although the difference was not significant ($P = .068$; Table 4), indicating that HIV-related immunodeficiency may play a role in the induction of chronic HBV infection. Among the 7 incident infections observed during LAM-ART, only 2 patients (28.6%) were symptomatic, had significant rise in ALT, and developed chronic HBV infection, and both of these infections were caused by LAM-resistant HBV (Table 5). The other 5 cases were asymptomatic and transient. Three of them were caused by LAM-sensitive strains and 1 was by LAM-resistant strain. HBsAg-positive serum sample was not available in the last case. LAM-resistant HBV was more frequently identified in analyzed incident infections during LAM-containing ART (50.0%) than in those during no ART and other ART (7.1%) ($P = .029$). Considered together, LAM seems to prevent acquisition of HBV infection, progression to symptomatic hepatitis, and development of chronic infection even after the development of infection, although these effects may be less pronounced in patients with LAM-resistant strains.

Among the 43 infection cases observed during total serological follow-up, HBsAg-positive samples were available in 34 cases and their HBV genotype was determined. Genotype A was the most frequent, as reported previously [10, 20–22], and genotypes B, G, and H were also identified. The rate of development of chronic infection was higher in genotype A than in other genotypes as previously reported [23], although the difference was not significant in our study. In the remaining 9 cases, only anti-HBc with (7 cases) or without (2 cases) anti-HBs were detected, although their samples were available and serologically analyzed at least every 3 months around the incident infection.

DISCUSSION

The results of this serological follow-up study indicated that LAM- and TDF-containing ART regimens protect against HBV incident infection. Furthermore, the results also suggested that LAM prevents progression to symptomatic hepatitis and development of chronic infection even after the development of HBV incident infection, provided such infection is caused by LAM-sensitive strains. However, it seems that LAM-resistant strains may evade this protective effect. One previous study that estimated the incidence of acute HBV infection among HIV-infected patients reported similar frequencies in patients receiving ART with and without LAM [5]. However, the authors defined immunoglobulin M anti-HBs positivity as a marker of HBV incident infection and did not exclude anti-HBc–positive patients at study entry. This probably made it difficult to distinguish incident infection from reactivation of chronic infection, as discussed in the report. In this study, we identified a